tbuckley/cabot-search huggingface dataset:
SAT0276 High Prevalence of Inflammatory Comorbidities in a 70 Cases-Cohort of Takayasu Arteritis: not Only by Chance?: Table 1.
Authors: M.C. Di Chio, S. Sartorelli, E. Tombetti, P. Aiello, A. Manfredi, M.G. Sabbadini, E. Baldissera
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Takayasu arteritis (TA) is a chronic idiopathic large-vessels vasculitis. Because of its relative rarity, little is known about its inflammatory comorbidities. Concomitant occurrence of TA and inflammatory bowel disease (IBD, &gt;70 cases), sarcoidosis (7 cases), relapsing polychondritis (RP, 2 cases) and erosive arthritis (2 cases) have been reported. It is unknown whether associations occur by chance or because of a common inflammatory background. <h3>Objectives</h3> Our purpose was to analyse inflammatory comorbidities in a cohort of TA patients (pts) followed at a single referral Center. <h3>Methods</h3> We retrospectively evaluated 70 TA pts referred at our Center between 2000 and 2013. Pts needed to fulfill the ACR classification criteria for TA to be included in the study. <h3>Results</h3> 15 TA pts (21%) had inflammatory comorbidities, i.e. RP, psoriasis, IBD, sarcoidosis, seronegative arthritis, episcleritis and coeliac disease (Tab.1). In 9/15 cases (60%) TA onset followed the inflammatory comorbidity, while in 5 cases (33%) TA preexisted. In one case the two conditions appeared simultaneously. TA onset followed the inflammatory comorbidity in 3 out of 4 pts with RP and in the two pts with IBD, while TA preceded sarcoidosis in both cases. Psoriasis, seronegative arthritis and episcleritis appeared either before or after TA. <h3>Conclusions</h3> Our data show the coexistence of inflammatory comorbidities in more than one fifth of TA pts. We observed a relatively high frequency (6%) of RP in our cohort. IBD occurred in 3% of our pts, while the expected prevalence of Crohn9s disease in TA, if present by chance alone, is approximately 0.05-0.2% (1). The high prevalence of inflammatory diseases in our cohort might suggest a role for a common background facilitating their association with TA. Further studies are needed to confirm our observation and to understand if association of TA and other inflammatory diseases could identify a subset of patients with different prognosis and response to therapies. <h3>References</h3> Reny JL et al. Association of Takayasu9s arteritis and Crohn9s disease. Results of a study on 44 Takayasu patients and review of the literature. Annales de medecine interne. 2003;154(2):85-90. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5759
Molecular Epidemiology of Antibiotic Resistance in Salmonella from Animals and Human Beings in the United States
Authors: Thomas F. O'Brien, John D. Hopkins, Elaine S. Gilleece, Antone A. Medeiros, Ralph L. Kent, Billie O. Blackburn, Marion B. Holmes, Joseph P. Reardon, James M. Vergeront, Wendy L. Schell, Eleanor Christenson, Marjorie L. Bissett, Erskine V. Morse
Journal: New England Journal of Medicine (1982)

We collected serotyped isolates of salmonella from reference laboratories in the United States, tested their susceptibility to antibiotics, and extracted plasmids from isolates that were resistant to a different combination of antibiotics from each of three serotypes. Restriction-endonuclease digestion showed that within each of the three groups, plasmid molecules from animal and human isolates were often identical or nearly identical. One serotype-plasmid combination appeared to be endemic in cattle in 20 states and infected 26 persons in two states. The human cases, which were not recognizably related except for their common plasmids, appeared to be clustered in time but geographically dispersed, like cases in previous outbreaks spread by food products. These findings suggest that resistance plasmids may be extensively shared between animal and human bacteria, and that spread of multiresistant strains of salmonella among animals and human beings, as observed in Britain, may have been undetected in the United States for lack of comparable surveillance.
SIMPLE ELECTROCARDIOGRAPHIC CRITERIA FOR DISCRIMINATING BETWEEN TAKOTSUBO CARDIOMYOPATHY AND REPERFUSED NON-Q WAVE ANTERIOR ACUTE MYOCARDIAL INFARCTION
Authors: Masami Kosuge, Toshiaki Ebina, Kiyoshi Hibi, Kengo Tsukahara, Noriaki Iwahashi, Nobuhiko Maejima, Eiichi Akiyama, Satoshi Umemura, Kazuo Kimura
Journal: Journal of the American College of Cardiology (2016)
SAT0007 Is Late Onset Rheumatoid Arthritis (Lora) Really a Distinct Entity of RA? Results from the Swiss Observational Cohort
Authors: R. Mueller, T. Kaegi, S. Haile, A. Finckh, J. von Kempis
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Rheumatoid arthritis (RA) is generally described as a disease with two peaks of onset, either late (late onset RA, LORA) or early (young onset RA, normal 30-55 years, YORA). Considering that the average age of the population is continuously rising, LORA will gain importance in the near future. Despite this growing importance LORA has not been the focus of much interest in the past. <h3>Objectives</h3> This study was set up to analyse disease activity and progression in LORA in comparison to YORA patients with early disease. <h3>Methods</h3> This is a cohort study within the Swiss RA registry SCQM. We included all patients with recent onset arthritis, either RA (disease duration ≤1 year) or undifferentiated, as diagnosed by the data-entering physician. Patients were followed up to 5 years. The cut off between YORA and LORA was operationally set at 60 years of age. Disease progression and activity was assessed based on DAS 28 and the progression of joint erosions using the Ratingen score. <h3>Results</h3> A total of 592 patients with early undifferentiated or RA was analysed. The age at disease onset had a Gaussian distribution, with a single peak at 60 years of age. 366 patients were 60 years or younger (YORA) and 226 patients were older (LORA) at disease onset. DAS 28 scores were significantly higher among LORA as compared to YORA patients (4.8 vs. 4.5, p = 0.049). Corticosteroids were used in 68% of LORA patients as a first line treatment, compared to 25.4% in YORA patients (<i>X</i><sup>2</sup> test, p &lt; 0.0001). DMARDs, on the other hand, were used in 100% of the YORA patients as first line treatment compared to 91.2% of the LORA patients. During follow up, new glucocorticoid, synthetic, or biologic DMARD were initiated in 32.8%/61.1%/14.1% of all decisions documented among YORA patients and 17.5%/54.6%/6.6% in LORA patients (<i>X</i><sup>2</sup> test, all p &lt; 0.0001. The DAS28 scores decreased in both groups over the observed time period, and the initial differences in disease activity vanished after 1/2 year and during the subsequent follow up. The Ratingen score was higher in LORA than in YORA patients at inclusion (12.7 vs. 5.6, p &lt; 0.0001). The rate of radiological progression at 5 years was similar comparing LORA and YORA (3.3 vs. 2.6, resp., p=0.64). The level of Ratingen scores at onset and during follow up over 5 years did not clearly separate LORA and YORA into two groups), but rather increased linearly when comparing the patients in groups per decade from 20 to 92 years of age. <h3>References</h3> Our results do not support the existence of a separate LORA subgroup with a distinct peak of incidence and/or course of the disease. <h3>Disclosure of Interest</h3> None Declared
The 2010 NCCN Clinical Practice Guidelines in Oncology on Prostate Cancer
Authors: James L. Mohler
Journal: Journal of the National Comprehensive Cancer Network (2010)

Dr. Mohler's clinical practice focuses up prostate cancer and robot-assisted laparoscopic surgery.His laboratory focuses on the role of the androgen receptor in racial differences in prostate cancer aggressiveness and recurrence during androgen deprivation therapy.
PWE-102 Infective Diarrhoea Complicating Ibd Vs Non-ibd Patients
Authors: S Mumtaz, S Kelly, UA Ahmad, S Everett
Journal: Gut (2014)

<h3>Introduction</h3> Clinical features associated with infective diarrhoea and flare up of Inflammatory Bowel Disease (IBD) are very similar and presents a challenge to gastroenterologists to distinguish the two especially at the initial presentation. <h3>Methods</h3> This was a retrospective cohort study for patients admitted to the gastroenterology department of a single tertiary care teaching hospital with a culture positive episode of bacterial infective diarrhoea, excluding Clostridium difficile. Data was collected from clinical notes of patients presenting over an 8 year period (2004–2012). We made comparisons between the cohorts of patients with and without IBD. <h3>Results</h3> 103 patients were included in the study; 13 had pre-existing IBD (7 UC, 6 Crohn’s), mean age [52 (17 – 82) IBD, 41 (18 – 103) non- IBD]. Organisms cultured; IBD [campylobacter 84% (11), salmonella 16% (2)], non-IBD [campylobacter 81% (73), salmonella 12% (11), ecoli 4% (4), shigella 2% (2)]. Median duration of symptoms was similar in both groups [4 days (IQR 2) IBD, 4 (IQR 6) non-IBD]. Patient gave history of (IBD vs non IBD); abdominal pain [77 vs. 90% OR 0.37 (95% CI: 0.08–1.6)], per rectal bleeding [46 vs. 52% OR 0.78 (95% CI: 0.24–2.5)], vomiting [38% vs. 43% OR 0.81 (95% CI: 0.24–2.71)]. Blood tests showed (IBD vs non IBD); platelet count [median 282 (IQR 130) vs. 237 (IQR 90)], CRP [56 (IQR 81) vs. 82 (IQR 102)], haemoglobin concentration [median 12.1 (IQR 2.4) vs. 14.3 (IQR 2.6)] and white cell count [median 8 (IQR 4) vs. 7 (IQR 3)]. A much higher proportion of patients in IBD group received steroids [77 vs 16% OR 16.6 (95% CI: 4.0–61)]. Patients in both group had comparable duration of hospital stay [median 5 (IQR 4) vs. 4 (IQR 3)]. <h3>Conclusion</h3> Infective diarrhoea presents similarly in patients who have a background of IBD to those that don’t but is more likely to be treated with steroids. A short history with abdominal pain and vomiting suggest an infective cause should be considered even if there is a established diagnosis of IBD. <h3>Disclosure of Interest</h3> None Declared.
AB0610 Mid-term efficacy of modified-release prednisone in glucocorticoids-naive patients with rheumatoid arthritis (RA)
Authors: S. Stisi, R. De Luca Bossa, G. Ciano, A. Marsico, C. Venditti, C. Marcassa
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Exogenous glucocorticoids (GC) added to DMARDs are effective in the treatment of RA. Timing of GC administration can improve the treatment; in particular, modified -release prednisone (MR-P, given at bedtime and released 4 h after ingestion) has been shown to improve RA management, reducing morning stiffness (MS) and interleukin-6 levels when compared to conventional, immediate-release prednisone; the improvement has been preliminary shown sustained for at least 12 months. <h3>Objectives</h3> We investigated the mid-term efficacy of MR-P chronotherapy for up to 4 months in unselected outpatients with active RA and inadequate response to DMARDs. <h3>Methods</h3> 70 consecutive patients with documented RA (average duration 109 months) and on active treatment with DMARDs and/or biologic agents referring from February 1st to April 30th 2011 at physicians discretion started low-dose P-MR and were followed bimonthly for 16 weeks. Clinical markers considered at first (T1) and T2-T3 follow-up visits included morning stiffness (min), patient- and physician global assessment (GA, 0–10 scale) and DAS 28 score. Temporal differences were analysed by variance analysis for repeated measures (ANOVA). <h3>Results</h3> Mean patients’ age was 55±15 (females 79%); 67.8% of patients were assuming methotrexate, 16.9%, leflunomide, 30.5% were assuming other DMARDs also in combination, and 32.2% were on biologics. During the follow-up, MR-P was well tolerated, only 1 patient dropped out prematurely switching to another GC; 3 (6.3%) other patients started ex-novo biologics. Among the 69 patients (98.4%) who completed the 4-month survey on MR-P, morning stiffness decreased from 65±43 min at the first visit (T1) to 30±24 min at the final T3 visit (p&lt;0.0001); patient- and physician- global assessment improved from 6.4±2.2 to 4.1±2.1 and from 5.9±2.3 to 3.8±2.1, respectively (both p&lt;0.001). DAS28 score decreased from 4.62±1.1 at T1 to 3.6±1.0 at T3 (p&lt;0.001). Daily MR-P starting dosage was 7.5±4.8 mg and decreased to 6.7±3.9 at T3 visit (p&lt;0.001). Daily assumption of analgesics and/or NSAIDs decreased from 35.3% to 5.1% (p 0.001). <h3>Conclusions</h3> In unselected RA patients on active antirheumatic treatment, modified-release prednisone (given at bedtime) induced a substantial benefit over a medium-term observation and was well tolerated. <h3>References</h3> Buttgereit et al. Lancet, 2008. <h3>Disclosure of Interest</h3> None Declared
PARE0021 Sick, but active - we can do everything you can do
Authors: L. Anders
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> It is time to get of the sofa! We are giving people with rheumatism an alternative way to train. For many people it is not enough just to walk and stay regularly fit. There are many who have rheumatism, but still think they can do just as others do. And we believe they can too. So we are helping them train for the biggest mountain bike race in Norway, Birkebeineren. The project is called !Sykt Aktiv”. <h3>Objectives</h3> There are 3 objectives. We want to show others that we can do what they can do. Rheumatism does not automatically mean that we have to stop doing all the fun stuff. And we need to show ourselves that we can do this. Even if you have pain in your muscles and joints, we will push extra hard and we shall succeed! Rebranding the Norwegian Rheumatism Association as a organization that takes challenges straight on and say. WE CAN DO IT! <h3>Methods</h3> Through advertisements and articles we have gathered a group of 28 people who have signed up for the project. Some were members already, some where not. They range from 22 and in fit shape to 50 and unfit. We will have 4 meetings before the race in august. The participants will meet a number of people who will talk to them about empowerment, training, exercise, cycling and nutrition. They will be given individual training schedules which will be renewed every 8 weeks. We are cooperating with several gyms, physiotherapists and others. <h3>Results</h3> In 2012 we only had two people cycling this race in our name. This year we have 28 who want to do so. We already have gotten a lot of attention on this project and others want to do other, similar activities. Our goal is that we get a lot of small groups around in the country that train a bit harder than the rest of us. This is not meant for everybody, but an alternative to those who feel they need the extra push. They might not need to participate in a bike race, but maybe run a local race, or climb a mountaintop. The sky is the limit, and we want you to try and reach for it. <h3>Conclusions</h3> We believe this is the right way to go to empower younger people in the organization and reach out to new potential members who want something different. They want to train, but know they have to respect their body. Here they can do so with others who understand their problems. <h3>Disclosure of Interest</h3> None Declared
SP0026 How to use the new data from eumusc.net to support national political campaigning
Authors: T. Uhlig
Journal: Annals of the Rheumatic Diseases (2013)

The Musculoskeletal Surveillance and Information network (EUMUSC.NET) is a project supported by the European Commission, EULAR and 23 centres across Europe. It intends to raise and harmonise quality of care and enable equity of care of rheumatic diseases and other musculoskeletal conditions across the EU Member States by developing and operationalising a European Musculoskeletal Conditions Surveillance and Information Network. EUMUSC.NET will thus identify the burden on individuals and society of these conditions across EU Member States; set standards of care both for individuals and for healthcare providers for osteoarthritis and rheumatoid arthritis; assess whether these are being achieved; and help to enhance facilitators and overcome the barriers to achieving these standards to enable the effective and equitable prevention and management of these condition in the Member States. This will lead to improved musculoskeletal health. One consequence of observed differences in outcomes of rheumatic diseases is to raise awareness of the public and of health professionals about the scale and impact of musculoskeletal conditions and of options for prevention and treatment. Patient and health professionals with their national organizations will be able to use data when acting as stakeholders. The EUMUSC.NET website serves now as a platform which provides facts and numbers on the settings of musculoskeletal diseases in the European countries. Within the EUMUSC.NET project ongoing work examines which facilitators help to make standards of care happen in the treatment of osteoarthritis and rheumatoid arthritis. In this work an online questionnaire widely queries a list of possible facilitators. Throughout Europe, patients, health care professionals and also health care policy makers are asked about their experience on implementation of standards of care. Hopefully, health care policy makers and administrators through this questionnaire are involved and reflect on how well existing standards of care are presently met in existing health care settings. When the responses from the questionnaires are evaluated we will be able to understand more why inequity exists within the field of rheumatology in the European countries. This will provide new information to be used as support for national political campaigning. <h3>Disclosure of Interest</h3> None Declared
Melatonin-Related Hypogonadotropic Hypogonadism
Authors: Manuel Puig-Domingo, Susan M. Webb, José Serrano, Miguel-Angel Peinado, Rosa Corcoy, Jordi Ruscalleda, Russel J. Reiter, Alberto de Leiva
Journal: New England Journal of Medicine (1992)

THE secretion of melatonin from the pineal gland is linked to the light–dark cycle, being greater at night in all species, including humans, and it is pulsatile.1 In humans the peak nocturnal plasma melatonin concentration declines progressively with age, being highest in infants and prepubertal children and lowest in elderly people. Melatonin profoundly influences reproductive function in seasonally breeding mammals. One such species is the Syrian hamster, in which pinealectomy leads to sustained reproductive activity and in which appropriately timed injections of melatonin inhibit reproductive function.2 It is less clear whether melatonin has regulatory actions on the reproductive system in . . .
P16.20 * ANALYSIS OF GLIOBLASTOMA'S PERITUMORAL BRAIN ZONE USING BIPHOTONIC MICROSCOPY
Authors: J. Lemee, A. Clavreul, S. Rakotoarimalala, D. Gindre, P. Menei
Journal: Neuro-Oncology (2014)

Glial tumors are primary tumors of the central nervous system. Gross total resection (GTR) of the tumor is the first step of its therapeutic management. Several techniques of per-operative analysis of the margin of the peritumoral brain zone (PBZ) have been developed in order to ensure a GTR of the tumor. We present here a new approach to the per-operative analysis of the PBZ using biphotonic microscopy analysis, a method allowing a fast and reproducible analysis of brain sample tissues. GB tumor zone, low-grade glioma and their respective PBZ were fixed on paraffine-embedded slices. These slices were analyzed using second harmonic generation microscopy (SHG) and two-photon excitation fluorescence (TPEF) microscopy. Data were collected and interpreted using a custom-wricen program with Labview, and compared to the histopathological diagnosis made by a certified neuropathologist. Each kind of brain tumor tissue and PBZ displayed a specific pattern in SHG and TPEF imaging. Also, distinction between tumor and PBZ was easy in SHG and TPEF analysis, allowing a clear vizualisation of the brain/tumor interface. SHG and TPEF imaging are fast and efficient methods allowing per-operative analysis of brain tumor tissue. The next step of our study will be to create an atlas of SHG and TPEF profile of the different brain tumors to allow direct per-operative analysis of PBZ without waiting for the pathological diagnosis, to ensure an optimal resection's quality.
Prospective Evaluation of Hearing Impairment as a Sequela of Acute Bacterial Meningitis
Authors: Philip R. Dodge, Hallowell Davis, Ralph D. Feigin, Sandra J. Holmes, Sheldon L. Kaplan, David P. Jubelirer, Barbara W. Stechenberg, Shirley K. Hirsh
Journal: New England Journal of Medicine (1984)

As part of a prospective study of acute bacterial meningitis in children, we studied for five years the hearing of 185 infants and children who had acute bacterial meningitis when they were more than one month of age. Nineteen (10.3 per cent) of the patients had persistent bilateral or unilateral sensorineural hearing loss. The incidence of hearing loss as determined by electric-response audiometry and conventional tests was 31 per cent with Streptococcus pneumoniae, 10.5 per cent with Neisseria meningitidis, and 6 per cent with Hemophilus influenzae infections. Transient conductive hearing impairment was found in 16 per cent of the sample, but in no case was there apparent improvement in a sensorineural deficit over time. The site of disease resulting in impaired hearing cannot be stated with certainty, but involvement of the inner ear or auditory nerve was suspected. The number of days of illness (symptoms) before hospitalization and institution of antibacterial treatment was not correlated with the development of sensorineural deafness.
Metabolic Effects of the Rice Diet in the Treatment of Hypertension
Authors: J. H. Currens, E. A. S. Reid, E. A. MacLachlan, F. A. Simeone
Journal: New England Journal of Medicine (1951)

DIETARY measures in the treatment of hypertension have been advocated periodically during the past fifty years and have been extensively reviewed recently.1 The metabolic effects of the rice diet have been reported previously in abstract form.2 Although the most recent empirical program, as outlined by Kempner,3 is of limited value in the treatment of most patients with hypertensive vascular disease because of its rigid restrictions on diet, rather striking improvements in the level of blood pressure and general condition have been observed in some patients. The physiologic changes responsible for such improvement as may occur in these patients are, however, . . .